Abeona Therapeutics Inc. (ABEO)

Market Cap	247.78M
Revenue (ttm)	n/a
Net Income (ttm)	-71.03M
Shares Out	43.47M
EPS (ttm)	-2.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200,283
Open	5.64
Previous Close	5.63
Day's Range	5.57 - 5.79
52-Week Range	3.05 - 9.01
Beta	1.44
Analysts	Strong Buy
Price Target	18.00 (+215.79%)
Earnings Date	Nov 14, 2024

About ABEO

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AI...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 19, 1980
• Employees: 84
• Stock Exchange: NASDAQ
• Ticker Symbol: ABEO
• Website: https://www.abeonatherapeutics.com

Financial Performance

In 2023, Abeona Therapeutics's revenue was $3.50 million, an increase of 147.52% compared to the previous year's $1.41 million. Losses were -$54.19 million, 24.6% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for ABEO stock is "Strong Buy." The 12-month stock price forecast is $18.0, which is an increase of 215.79% from the latest price.

Price Target

$18.0

(215.79% upside)

Analyst Consensus: Strong Buy